Document Detail


Combined treatment of invasive giant prolactinomas.
MedLine Citation:
PMID:  16411070     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The management of invasive giant prolactinomas (IGP) has been an area of some controversy. The relative roles of transsphenoidal surgery, craniotomy, radiation therapy and dopamine agonist based medical therapy are gradually becoming clarified. We report the results of management of 30 patients with IGP. Surgery was the initial therapy in 18 patients and was nearly always followed by adjunctive treatment with radiotherapy and/or bromocriptine. A second group of 12 patients had initial therapy with bromocriptine; 6 had subsequent radiotherapy and only 1 had transsphenoidal surgery. Outcomes with regard to relief of mass effect, visual improvement, pituitary function and complications of therapy were superior in the bromocriptine treated patients.
Authors:
Chonjiang Yu; Zhebao Wu; Jian Gong
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Pituitary     Volume:  8     ISSN:  1386-341X     ISO Abbreviation:  Pituitary     Publication Date:  2005  
Date Detail:
Created Date:  2006-01-13     Completed Date:  2006-03-06     Revised Date:  2009-11-03    
Medline Journal Info:
Nlm Unique ID:  9814578     Medline TA:  Pituitary     Country:  United States    
Other Details:
Languages:  eng     Pagination:  61-5     Citation Subset:  IM    
Affiliation:
Beijing Neurosurgical Institute, Beijing 10050, PR China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Bromocriptine / therapeutic use
Combined Modality Therapy
Craniotomy
Dopamine Agonists / therapeutic use
Female
Follow-Up Studies
Humans
Male
Middle Aged
Neoplasm Invasiveness
Pituitary Gland / pathology,  physiopathology
Pituitary Neoplasms / drug therapy,  radiotherapy,  surgery,  therapy*
Prolactin / blood
Prolactinoma / drug therapy,  radiotherapy,  surgery,  therapy*
Treatment Outcome
Chemical
Reg. No./Substance:
0/Dopamine Agonists; 25614-03-3/Bromocriptine; 9002-62-4/Prolactin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Surgical outcomes in hyporesponsive prolactinomas: analysis of patients with resistance or intoleran...
Next Document:  Modeling and observer design for recombinant Escherichia coli strain.